NCT07181941View on ClinicalTrials.gov

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Recurrent Multiple MyelomaRefractory Multiple MyelomaTriple-Class Refractory Multiple Myeloma
Interventions
BIOLOGICAL

Linvoseltamab

Given IV

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER